2) ICH E2D ガイドライン. 承認後の安全性情報の取扱い:緊急報告のための用語の定義と報告の基準について. 2005.
3) Paludetto M-N, Olivier-Abbal P, Montastruc J-L. Is spontaneous reporting always the most important information supporting drug withdrawals for pharmacovigilance reasons in France ?. Pharmacoepidemiol Drug Saf 2012; 21: 1289-94.
4) The US Food and Drug Administration, “FDA Adverse Event Reporting System (FAERS) : The US food and drug administration, 2017,” https://www.fda.gov/drugs/drug-approvals-and-databases/fda-adverse-event-reporting-system-faers\n\n (accessed 8 December, 2019)
5) The European Medicines Agency, “Eudravigilance amsterdam: The European Medicines Agency; 2019,” https://www.ema.europa.eu/en/human-regulatory/research-development/pharmacovigilance/eudravigilance (accessed 8 December, 2019)